Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Deutsches Krebsforschungszentrum currently manages 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 6 distinct examiners and 6 distinct art units, indicating that the organization's patent strategy involves diverse biological or pharmaceutical sub-disciplines. Such a distribution requires practitioners to adapt to the specific tendencies of multiple USPTO departments simultaneously, as no two pending matters share the same examiner or art unit.
The busiest examiner for this portfolio is LEE, CHIHYI NMN, who is responsible for 1 pending office action. Because the total of 6 pending office actions is spread across an equal number of individuals, LEE, CHIHYI NMN holds a workload equal to every other examiner currently engaged with the portfolio. This parity between pending actions and examiners means that prosecution success depends on navigating individual examiner perspectives rather than consolidating efforts under a single primary contact.
The presence of 6 distinct art units reflects a lack of concentration in any single specialized group within the Biotechnology & Pharmaceuticals sector. This variety in art units may lead to different examination timelines and varying levels of scrutiny based on the specific technological focus of each unit. Practitioners must coordinate across these diverse units to maintain consistency in their prosecution strategy, as the current workload is not concentrated in any single specialized silo.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 3 (50%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
| BURKHART, MICHAEL D | 1 | 62.3% | +11.7% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| LEE, ANDREW P | 1 | 48.3% | +23.1% |
| WESTERBERG, NISSA M | 1 | 23.4% | +37.1% |
| MEYERING, SHABANA SHABBEER | 1 | 70.6% | +42.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17279914 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS | WESTERBERG, NISSA M | 47d |
| 18017636 | 5' S/MAR APPLICATIONS | BURKHART, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17279914 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS | WESTERBERG, NISSA M | 47d |
| 18275978 | MAP4K1 INHIBITORS | LEE, CHIHYI NMN | — |
| 18017636 | 5' S/MAR APPLICATIONS | BURKHART, MICHAEL D | — |
| 17787855 | LEUKEMIA TREATMENT | AEDER, SEAN E | — |
| 17634930 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | LEE, ANDREW P | — |
| 16648768 | NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS | MEYERING, SHABANA SHABBEER | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1638 | 1 |
| 1642 | 1 |
| 1691 | 1 |
| 1618 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18275978 | MAP4K1 INHIBITORS | LEE, CHIHYI NMN | 1628 | §103§112DP | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18017636 | 5' S/MAR APPLICATIONS | BURKHART, MICHAEL D | 1638 | §102§103 | Non-Final OA | — | Pending | Jan 23, 2023 |
| 17787855 | LEUKEMIA TREATMENT | AEDER, SEAN E | 1642 | §103 | Final Rejection | — | Pending | Jun 21, 2022 |
| 17634930 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | LEE, ANDREW P | 1691 | §112 | Non-Final OA | — | Pending | Feb 11, 2022 |
| 17279914 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PSMA-EXPRESSING CANCERS | WESTERBERG, NISSA M | 1618 | §103DP | Final Rejection | 47d | Pending | Mar 25, 2021 |
| 16648768 | NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS | MEYERING, SHABANA SHABBEER | 1635 | §103DP | Non-Final OA | — | Pending | Mar 19, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial